Cyndeo Wealth Partners LLC Acquires 6,404 Shares of Johnson & Johnson (NYSE:JNJ)

Cyndeo Wealth Partners LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,856 shares of the company’s stock after purchasing an additional 6,404 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Johnson & Johnson were worth $9,700,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of JNJ. Innealta Capital LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $43,000. Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $46,000. Fairway Wealth LLC increased its position in shares of Johnson & Johnson by 217.1% during the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after purchasing an additional 228 shares during the period. Finally, Quarry LP acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $49,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Trading Up 0.4 %

JNJ stock opened at $165.12 on Monday. The company has a market cap of $397.39 billion, a P/E ratio of 10.29, a PEG ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The business has a fifty day moving average of $162.98 and a 200-day moving average of $154.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.66 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.